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ASK1 (MAP3K5) is transcriptionally upregulated
by E2F1 in adipose tissue in obesity, molecularly
deﬁning a human dys-metabolic obese
phenotype
Yulia Haim 1,2, Matthias Blüher 3, Daniel Konrad 4, Nir Goldstein 1, Nora Klöting 3, Ilana Harman-Boehm 5,
Boris Kirshtein 6, Doron Ginsberg 7, Tanya Tarnovscki 1, Yftach Gepner 8, Iris Shai 8, Assaf Rudich 1,2,*
ABSTRACT
Objective: Obesity variably disrupts human health, but molecular-based patients’ health-risk stratiﬁcation is limited. Adipose tissue (AT) stresses
may link obesity with metabolic dysfunction, but how they signal in humans remains poorly-characterized. We hypothesized that a transcriptional
AT stress-signaling cascade involving E2F1 and ASK1 (MAP3K5) molecularly deﬁnes high-risk obese subtype.
Methods: ASK1 expression in human AT biopsies was determined by real-time PCR analysis, and chromatin immunoprecipitation (ChIP) adopted to
AT explants was used to evaluate the binding of E2F1 to the ASK1 promoter. Dual luciferase assay was used to measure ASK1 promoter activity in
HEK293 cells. Effects of E2F1 knockout/knockdown in adipocytes was assessed utilizing mouse-embryonal-ﬁbroblasts (MEF)-derived adipocyte-like
cells from WT and E2F1/ mice and by siRNA, respectively. ASK1 depletion in adipocytes was studied in MEF-derived adipocyte-like cells from WT
and adipose tissue-speciﬁc ASK1 knockout mice (ASK1-ATKO).
Results: Human visceral-AT ASK1 mRNA (N ¼ 436) was associated with parameters of obesity-related cardio-metabolic morbidity. Adjustment
for E2F1 expression attenuated the association of ASK1 with fasting glucose, insulin resistance, circulating IL-6, and lipids (triglycerides, HDL-
cholesterol), even after adjusting for BMI. Chromatin-immunoprecipitation in human-AT explants revealed BMI-associated increased occupancy of
the ASK1 promoter by E2F1 (r2 ¼ 0.847, p < 0.01). In adipocytes, siRNA-mediated E2F1-knockdown, and MEF-derived adipocytes of E2F1-
knockout mice, demonstrated decreased ASK1 expression and signaling to JNK. Mutation/truncation of an E2F1 binding site in hASK1
promoter decreased E2F1-induced ASK1 promoter activity, whereas E2F1-mediated sensitization of ASK1 promoter to further activation by
TNFa was inhibited by JNK-inhibitor. Finally, MEF-derived adipocytes from adipocyte-speciﬁc ASK1-knockout mice exhibited lower leptin and
higher adiponectin expression and secretion, and resistance to the effects of TNFa.
Conclusions: AT E2F1 eASK1 molecularly deﬁnes a metabolically-detrimental obese sub-phenotype. Functionally, it may negatively affect AT
endocrine function, linking AT stress to whole-body metabolic dysfunction.
 2017 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Obese sub-phenotypes associated with increased cardio-metabolic
risk are characterized by metabolically and endocrinologically
dysfunctional AT that is thought to contribute to the development of
obesity-associated morbidities [1e3]. As an underlying mechanism for
dysfunctional AT, various AT stresses have been recognized in obesity,
including inﬂammation, endoplasmic reticulum stress, hypoxia, and
oxidative stress [4e8]. Much effort has been invested in understanding
which types of besity-induced AT stress is most signiﬁcant, and the
emerging picture is of an inter-connected “network of stresses” [9].
Yet, the molecular pathways activated by these stresses, linking them
with the functional alterations they are claimed to induce, are incom-
pletely mapped. The interest in this extends beyond understanding the
basic pathogenic mechanisms; such AT stress-response network(s),
particularly when identiﬁed in human-AT, may constitute a molecular
signature that could be used for improved patient stratiﬁcation and
identiﬁcation of targets of future pharmacological therapies.
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Several signaling pathways were reported to be activated in AT in
obesity, mostly in mouse models [10e17]. In human-AT in obesity,
one such stress-responsive pathway activated particularly in the intra-
abdominal visceral fat is a MAP kinase signaling cascade comprised of
MAP3K ASK1 (MAP3K5), MAP2Ks MKK4 and 3/6, MAPKs p38MAPK,
and JNK [18,19]. We demonstrated that ASK1 expression (both mRNA
and protein levels) was up-regulated in obesity and, more importantly,
that ASK1 mRNA levels in omental fat constituted, by multivariate
analysis, a statistical predictor of whole-body insulin resistance in-
dependent of age, sex, BMI, and additional confounders [18]. In cellular
systems, ASK1 has been recognized to respond to the same stresses
that are implicated in AT in obesity, in particular to inﬂammation,
oxidative and ER stresses [20e22]. Functionally related to obesity,
genetic variants of ASK1 that resulted in decreased ASK1 expression in
muscle were associated with insulin resistance in Pima Indians [23]. In
mice, whole-body knockout of ASK1 predisposed to obesity, potentially
by interfering with brown fat function [24]. These two studies assign a
potential role for ASK1 in whole-body metabolic (dys)regulation. Yet,
the impact of ASK1 over-expression in humans, particularly in white
adipose tissue, and the molecular underpinnings for its elevated
expression, remain unknown.
As a MAP kinase, ASK1 was mainly shown to be regulated by phos-
phorylation and/or oxidation of its inhibitory partner thioredoxin
[22,25,26]. Yet, transcriptional regulation of ASK1 was also reported.
The transcription factor E2F1, mainly known as a cell cycle regulator,
binds directly to the ASK1 promoter and up-regulates its expression in
cancer cells [27e29]. Recently, we reported signiﬁcant gene regula-
tory functions for E2F1 in adipocytes, cells that are post-mitotic [30].
E2F1 was up-regulated in omental AT in obesity in the adipocyte cell
fraction, increasing not only the expression of several autophagy genes
but also the autophagy process itself [30]. This ﬁnding is consistent
with other studies implicating non-cell-cycle related, including meta-
bolic, functions of E2F1 (and of other classical cell-cycle regulators)
[31e35]. In the present study, we test the hypothesis that ASK1
expression and its downstream signals are regulated by E2F1 in
human-AT in obesity. Both clinically and mechanistically, we sys-
tematically investigated the possibility that the E2F1-ASK1 network
molecularly deﬁnes an obese sub-phenotype characterized by AT
stress and metabolic dysfunction.
2. MATERIAL AND METHODS
2.1. Study population
Participants were from two cohorts, one in Beer-Sheva, Israel (N¼ 16)
and one in Leipzig, Germany (N ¼ 436), both of which have been
described in a previous publication [30]. AT biopsies were analyzed
exactly as described in previous publications [18,19,36e38]. All
procedures were approved in advance by the ethics committee and
were conducted in accordance with Declaration of Helsinki guidelines.
In brief, participants were recruited before undergoing abdominal
surgery (primarily bariatric surgery and elective cholecystectomy) after
providing written informed consent. Paired subcutaneous (Sc) and Om
AT biopsies were obtained during surgery and immediately delivered to
the laboratory where they were processed for mRNA expression or
chromatin immunoprecipitation (ChIP) studies.
2.2. Materials
Tissue culture media were from Biological Industries (Beit-Haemek,
Israel). Indomethacin (I7378), dexamethasone (D4902), 3-
isobutylmethylxanthine (IBMX) (I7018), and rosiglitazone (R2408)
were from SigmaeAldrich. Recombinant murine/human TNF (410-MT,
210-TA respectively) and murine IL-1b (401-ML) were purchased from
R&D Systems Inc.
2.3. Cell culture
Human embryonic kidney (HEK) 293T cells (ATCC, Manassas, VA) were
grown in DMEM containing 4.5 mM glucose, 10%FBS, 2 mM L-
glutamine, and 100 U/ml penicillin-streptomycin. Medium was
changed every other day. For Western blot analysis experiments,
HEK293 were treated with TNF (10 ng/ml) with or without SP600125
for 24 h. Mouse embryonal ﬁbroblasts (MEF) from E2F1/ and WT
mice (kindly provided by Prof. Gustavo Leone, Department of molecular
virology and genetics, College of Medicine and Public Health, Ohio
State University, Ohio, USA) were cultured in DMEM containing 4.5 mM
glucose, 10%FBS, 2 mM L-glutamine, and 100 U/ml penicillin-
streptomycin. Differentiation into adipocytes was performed as previ-
ously described [30,39]. For Western blot analyses and leptin/adipo-
nectin concentration measurements, adipocyte-like MEFs were treated
with TNFa (10 ng/ml) þ IL-1b (10 ng/ml) for 24 h. Epididymal pre-
adipocytes were grown and differentiated into mature adipocytes as
previously described [40]. For quantitative Real-Time PCR experi-
ments, epididymal adipocytes were treated for 4 or 24 h with one of
the following treatments: TNFa (10 ng/ml)/Fas ligand (2 ng/ml)/
Glucose oxidase (50 mU/ml) and Tunicamycin (5 mg/ml). For ASK1
depletion in adipocyte-like cells, we utilized MEF from adipocyte-
speciﬁc ASK1-KO mice and control littermates. Targeted embryonic
stem cell clones with exon 14 (whose deletion will lead to a frame shift)
of ASK1 ﬂanked by loxP sites and a FRT-ﬂanked selection cassette
were bought from the European Conditional Mouse Mutagenesis
Program (EUCOMM) to generate ﬂoxed ASK1 mice. To obtain
adipocyte-speciﬁc ASK1 depletion, homozygous ASK1 ﬂoxed mice
were bred to mice that express the Cre enzyme driven by the
adipocyte-speciﬁc adiponectin promoter (Adipoq-Cre mice) [41].
2.4. RNA extraction and quantitative real-time PCR
Total RNA from epididymal adipocytes or MEFs adipocyte-like cells
was extracted using the RNeasy lipid tissue mini-kit (74804, Qiagen)
and quantiﬁed using nano-drop. Then, 2 mg of RNA were reverse-
transcribed with high capacity cDNA reverse transcriptase kit
(4374966, Life Technologies Inc.). Taqman system (4369016, Life
Technologies, Inc.) was used for real-time PCR ampliﬁcation. Extrac-
tion of total RNA from paired human-AT biopsies (Leipzig cohort) was
done according to a previously described protocol [18]. Relative gene
expression was obtained after normalization to endogenous control
genes, using formula 2DDCt and speciﬁc primers (Supplementary
Table 1).
2.5. E2f1 knockdown by small interfering RNA (siRNA) transfection
E2f1 and non-speciﬁc sequence control (NS) siRNAs ON-TARGET plus
smart pools were obtained from Dharmacon (Thermo Fisher Scientiﬁc
Inc., Waltham, MA). Each siRNA was transfected into differentiated
epididymal adipocyte cell line at a concentration of 1 nmol/well by
electroporation with GenePulser Xcell (BioRad Laboratories Inc., Her-
cules, CA). Brieﬂy, epididymal adipocytes were trypsinized on the third
day (of 6 days) of differentiation process from 150 mm culture plate
dish. Cells were rinsed three times with PBS, centrifuged (5 min,
1200 rpm, room temperature), and after last wash supernatant was
aspirated. Next, cells were re-suspended in 400 ml of Ingenio
Electroporation Solution (Mirus Bio LLC, Madison, WI) with 4 nmol of
E2f1 or NS siRNA, and electroporation was performed in accordance
with the manufacturer’s instructions using the optimal program (170 V,
10 ms, two pulses). After electroporation, cells were cultured in
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complete medium (DMEM 20% FCS). 24 h post-electroporation, cells
were incubated with TNF(10 ng/ml) in DMEM 0.5%BSA for additional
24 h. Cells were rinsed 3 times with ice-cold PBS and subjected to
either quantitative real-time PCR or Western blot analysis.
2.6. Transient transfection and promoter activity assay
HEK293 cells were seeded in 24 well plate in 1 ml/well of DMEM 10%
FCS. 24 h later, medium was changed to a fresh 0.5 ml/well, and cells
were transfected using jetPEI reagent (101-01N, Poly-plus trans-
fection Inc.), according to manufacturer’s instructions. Brieﬂy,
200 ng/well of the expression plasmid (pCMV-empty/E2F1), 200 ng/
well of the ﬁreﬂy luciferase reporter plasmids (ASK1WT/ASK1m1/
ASK1m2/ASK1m3), and 2 ng/well of the Renilla luciferase reporter
plasmid were used for each transfection. 4 h after transfection,
medium was changed to fresh DMEM 10%FBS with or without TNFa
(10 ng/ml) and with or without SP600125. Cells were lysed 24 h after
incubation with or without TNFa 10 ng/ml and with or without
SP600125 treatments by applying 100 ml of Passive Lysis Buffer of
the Dual Luciferase Reporter Assay Kit (E-1910, Promega Corpora-
tion) into each well of the 24-well plate. 20 ml of cell lysate were used
for the luciferase reporter assay with the same kit, according to the
manufacturer’s protocol. Luminescence intensity was quantiﬁed in a
GloMax 20/20n Luminometer (Promega Corporation). The experi-
ments were performed at least in triplicate. As a control for trans-
fection efﬁciency, the ﬁreﬂy luciferase activity values were normalized
to the Renilla luciferase activity values.
2.7. Promoter analysis and site-directed mutagenesis
Human ASK1 promoter (1000 bp upstream to the transcription start
site-TSS and 500 bp downstream) was analyzed for predicted E2F1
binding sites using MatInspector software (Genomatix Tools). Promoter
analysis produced one predicted E2F1 binding site on ASK1 promoter,
which was located 384 bp upstream the TSS with a score probability of
0.84 (1-highest probability). Using site-directed mutagenesis kit
(Stratagene, Santa Clara, CA), E2F1-predicted binding site on the
ASK1-Luc plasmid was mutated at the core sequence (CGCG) gener-
ating 3 new mutated ASK1-Luc plasmids, as indicated in Figure 4B.
Mutations/deletions were validated by sequencing.
2.8. Leptin and adiponectin concentrations
Leptin and adiponectin were measured in cultured media with or
without TNFa (10 ng/ml) þ IL-1b (10 ng/ml) treatment for 24 h by
ELISA (MOB00, MRP300, respectively, R&D Systems Inc.).
2.9. Chromatin immunoprecipitation (ChIP)
ChIP from fresh human-AT explants was performed following a
recently-described protocol [42]. Brieﬂy, 1 g of Sc or Om AT was
minced into small pieces using two pairs of sterile scissors. Next,
samples were cross-linked with 1% of formaldehyde at 37 C for
8 min. Cross-linking reaction was quenched using 0.125 M glycine.
Samples were washed with ice cold PBS 3 times, and, following the
last wash, adipocyte lysis buffer was added. After 15 min of incubation
on ice, samples were homogenized using a Dounce homogenizer
(loose pestle, 20 strokes, Wheaton). Nuclei were released after 20
additional strokes using a tight pestle. After sonication, the protein-DNA
complexes were immunoprecipitated using anti-ICAM (sc-7891X, as
negative control), anti-RNA poll 2 (sc-21750X, as positive control) and
anti-E2F1 antibodies (sc-193X, all from Santa Cruz Biotechnology). After
cross-linking reversal at 65 C for 4 h, DNA was puriﬁed using the
phenol-chloroform method. Primers (50 to 30) for end-point PCR or
quantitative real-time PCR were as follows: ASK1- Fw e
GTGCTGGACCGCTTTTACAATGC, Rve CAGTTCAAGTCGATCGCATGGAC.
Input (diluted 1/300) was used as a normalizing control.
2.10. Statistical analysis
Data, expressed as the mean  SD, and calculations were performed
using GraphPad software. Statistically signiﬁcant differences between
two groups were evaluated using paired or unpaired Student’s-t-test,
as indicated in the ﬁgure legends. Correlation between BMI and E2F1
binding to ASK1 promoter was assessed by linear regression. Clinical
and biochemical characteristics of the study population were cross-
classiﬁed across quintiles of visceral (Om) ASK1 mRNA expression in
order to control any un-normal variable distribution. p of trend was
calculated across quintiles, and ANOVA with Tuckey post-hoc test was
used to assess signiﬁcance between each quintile pairs. We further
assessed beta coefﬁcients to Om-ASK1 by performing step-wise
multivariate linear regression models using SPSS statistical package.
3. RESULTS
3.1. A putative E2F1-ASK1 pathway in human adipose tissue in
obesity
Previously, we reported that omental (Om) AT-ASK1 mRNA levels were
independent statistical predictors of whole-body insulin sensitivity by
multivariate models that considered multiple potential confounders of
this association (age, BMI, serum lipids and FFA, leptin, adiponectin,
and IL-6) [18]. Moreover, we demonstrated that although AT-ASK1
expression could be largely attributed in lean persons to the non-
adipocyte stromal-vascular cells, the increased expression of this
gene that accompanied visceral adiposity was largely contributed by
the adipocytes. To assess the relation of Om-ASK1 mRNA levels with
additional clinical characteristics of the patients, with emphasis on
obesity-related cardio-metabolic parameters, we utilized a larger,
previously-described patient dataset [30], stratifying the data into
quintiles of Om-ASK1mRNA (Table S1). Om-ASK1mRNA levels did not
associate with age (Figure 1A). However, highly-signiﬁcant associa-
tions (p of trend<0.05) were observed with BMI, fasting plasma
glucose, and insulin resistance (as determined by hyper-insulinemic-
euglycemic clamp), supporting the results of our previous work [18]
(Figure 1A, Table S1). Furthermore, we found a signiﬁcant associa-
tion between Om-ASK1 mRNA levels and adipocyte diameter and
correlations with markers of obesity-associated cardio-metabolic risk,
such as waist circumference and visceral fat area (Figure 1B). More-
over, high circulating levels of IL-6, triglycerides, free fatty acids (FFA),
and leptin and low circulating levels of adiponectin were signiﬁcantly
associated with higher Om-ASK1 mRNA levels (p < 0.001 for all,
Figure 1C). Indeed, only 1% of the population in the lower Om-ASK1
mRNA quintile was diagnosed with diabetes, whereas in the top
quintile, more than 60% were diabetic patients (Figure 1A). Among the
sub-group of obese patients (BMI 30 kg/m2, N ¼ 270), Om-ASK1
mRNA associated with fasting glucose, HbA1c, insulin resistance,
serum lipids, and with low circulating high-Mw-adiponectin, associ-
ations that remained signiﬁcant even when further adjusting for BMI (in
addition to age and sex) (Figure 1D). Furthermore, signiﬁcant associ-
ations could be demonstrated in both obese subtypes categorized by
abdominal fat distribution pattern (subcutaneously versus viscerally e
obese) (Figure 1D).
MAP kinases are mainly thought to be regulated by phosphorylation. In
cancer cells, transcriptional regulation of ASK1 was also demonstrated
by the cell-cycle regulator E2F1 [27e29]. Recently, we reported that
E2F1 expression is increased in Om of intra-abdominally obese
humans and may act to activate non-cell-cycle-related genes [30].
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Figure 1: Correlation of ASK1 mRNA expression levels in human omental AT with different clinical parameters. (AeC) Clinical parameters of 436 persons were cross-
classiﬁed across quintiles of Om-ASK1 mRNA expression. p of trend (by linear regression) and ANOVA þ post-hoc analysis of inter-quintile signiﬁcance are presented in Table S1.
(D) Multivariate analyses of the association between OM-ASK1 mRNA and various clinical parameters among the entire obese subgroup (N ¼ 270), and in obese patients with
predominant subcutaneous obesity (Obese-SC, N ¼ 206, deﬁned as abdominal visceral/subcutaneous area<50% by L3-L4 CT or MRI imaging) or with predominant visceral
adiposity (Obese-Om, N ¼ 64). All models are adjusted for age and sex, and for the entire obese subgroup an additional model is presented also adjusted for BMI.
Original Article
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Therefore, we assessed whether increased BMI was associated in
human-AT with greater occupancy of the ASK1 promoter by E2F1.
Using a chromatin immunoprecipitation (ChIP) protocol adopted to
human-AT [42], a highly signiﬁcant correlation between BMI and E2F1
binding to the ASK1 promoter could be observed in both Om and Sc fat,
though the effect of BMI was more robust for Om (Om: r ¼ 0.920,
p < 0.001; Sc: r ¼ 0.650, p ¼ 0.009, Figure 2A). Next, we adjusted
the associations of ASK1 with several obesity-related parameters for
BMI and for E2F1 to assess if they may share a common mechanistic
pathway. ASK1 remained signiﬁcantly associated with insulin resis-
tance, high triglycerides, and, importantly, with low adiponectin, even
after adjusting the model for BMI and E2F1 (Figure 2B). Yet, the as-
sociations of Om-ASK1 with all parameters were attenuated by
adjusting for the expression of E2F1 mRNA in Om AT. Collectively,
using a large human-AT biobank, we demonstrate that Om-ASK1
expression may share a common path with E2F1 in their association
with major clinical parameters indicating AT dysfunction and increased
cardio-metabolic risk. Moreover, molecularly, higher BMI associates
with increased occupancy of the ASK1 promoter by E2F1.
3.2. Molecular links between E2F1 and ASK1 regulation
To better deﬁne the molecular mechanisms and triggers for increased
adipocyte ASK1 expression and to evaluate the contribution of adi-
pocytes, we utilized cellular models. A differentiated murine epidid-
ymal adipocyte cell line was utilized to determine potential individual
triggers relevant to the AT milieu in obesity, which could increase ASK1
mRNA levels. To this end, inﬂammatory stimuli such as the prototypical
pro-inﬂammatory cytokine TNFa, and FasL, and an oxidative envi-
ronment induced by adding the H2O2 generating enzyme glucose ox-
idase (GO) to the medium, increased Ask1 mRNA byw2-fold at 24 h
(Figure 3A). At 4 h stimulation the responses differed, likely repre-
senting unique signaling components of the different stimuli that
Figure 2: Effect of BMI on E2F1 binding to the ASK1 promoter and associations between Om-ASK1 expression levels and different clinical characteristics. (A)
Formaldehyde cross-linked chromatin from 16 paired human (Om and Sc) ATs was subjected to ChIP experiments. Immunoprecipitation of E2F1 containing complexes was
performed using anti-E2F1 antibody. Anti-POLR2 (polymerase RNA II), was used as positive control and anti-ICAM1 (intercellular adhesion molecule 1) was used as negative
control. After isolation of bound DNA, end-point PCR and quantitative real time PCR were performed for a 300 bp region of the endogenous human ASK1 promoter. Quantitative real
time PCR results were analyzed using linear regression. Inputs indicate PCR performed on DNA (diluted 1:300) without any immunoprecipitation. (B) Multi variate models to assess
associations between Om-ASK1 mRNA levels and parameters shown in Figure 1 as continuous variables. Values are the b coefﬁcient of association, with model 1 adjusted for age
and sex, model 2 for age, sex, and BMI, and model 3 adjusted for age, sex, BMI, and Om-E2F1 mRNA expression. * Associations with p values <0.05. GIR; glucose infusion rate
during hyper-insulinemic euglycemic clamp, FPG; fasting plasma glucose, HDL-cholesterol; high-density lipoprotein cholesterol, TG; triglycerides, WC; waist circumference, ad.
diam.; adipocyte diameter.
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Figure 3: Increase in transcription of ASK1 gene by mimickers of obesity-associated AT stresses is attenuated by absence of E2F1 in adipocytes. (A) Epididymal
adipocytes were treated with several stress inducers (TNFa 10 ng/ml, FasL 1 ng/ml, GO 50 mU/ml, and Tunicamycin 5 mg/ml) for 4 or 24 h and subjected to quantitative real-time
PCR analysis. The expression was normalized to b-actin and Hprt1. Results are mean  SD of n ¼ 5 independent experiments. ***p < 0.001 4/24 h of each treatment vs. con. (B)
Epididymal adipocytes were incubated with TNFa (10 ng/ml) or TNFa (10 ng/ml) þ Act. D. (1 mg/ml) for 4 h and subjected to quantitative real-time PCR analysis. The expression
was normalized to b-actin and Hprt1. Results are mean  SD of n ¼ 3 independent experiments. ***p < 0.001 TNFa only versus con. ###p < 0.001 Act. D. (C, D) Epididymal
adipocytes were transfected with. E2f1 siRNA (siE2f1) or non-speciﬁc siRNA (siNS) using electroporation. 24 h after transfection, adipocytes were incubated with TNFa (10 ng/ml)
for an additional 24 h and analyzed using either quantitative real-time PCR or Western blot. Each transcript expression was normalized to b-actin and Hprt1 mRNA levels. b-actin
was used as a loading control on the gel. Results are mean  SD of 3 independent experiments. ***p < 0.001 siE2f1con and TNFa vs. siNS con (middle graph), siNS TNFa vs.
siNS con (right graph). **p < 0.01 siE2f1 TNFa vs. siE2F1 con. ##p < 0.01 siE2f1 TNFa vs. siNS TNFa. MEF-derived adipocyte-like cells from WT and E2F1/ were treated with
TNFa 10 ng/ml þ IL-1b 10 ng/ml for 24 h and subjected to Western blot analysis. Shown are representative blots (E) and densitometry graphs (FeI) of n ¼ 3 independent
experiments. b-actin was used as a loading control. *p < 0.05 E2F1/ con or WT TNFa 10 ng/ml þ IL-1b 10 ng/ml vs. WT con. #p < 0.05 E2F1/ TNFa 10 ng/ml þ IL-1b
10 ng/ml vs. E2F1/ con.
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Figure 4: ASK1 promoter activity is elevated by E2F1 over-expression and JNK phosphorylation input in HEK293 cells. (A) HEK293 cells were transfected with pA3-ASK1-
Luc and an empty pcDNA3 (EV) or pcDNA3-E2F1 (E2F1WT) or pcDNA3-E2F1-mut (E2F1mut). After normalization to endogenous control (RSV-Renilla), an empty pcDNA3 (EV) was
determined as basal luciferase activity. ASK1-promoter activity was measured after treatment with TNFa (10 ng/ml) for 24 h using Dual Luciferase Assay. Results are mean  SD
of n ¼ 7 independent experiments. ***p < 0.001 con E2F1WT vs. con EV. ###p < 0.001 TNFa 10 ng/ml E2F1WT vs. con E2F1WT. (B) Wild-type (WT) and mutated constructs of
predicted E2F1-binding site on ASK1-promoter area by Met-Inspector software. E2F1 binding to the ASK1 promoter is mediated by physical interactions between E2F1 and a core
sequence of the binding site (underlined sequence of four nucleotides). Two point mutations (ASK1m1 and ASK1m2) and one deletion mutation (ASK1m3) of this core sequence were
made by using mutagenesis kit as elaborated in the Methods, and their effect on ASK1 promoter activity is presented in (C). After normalization to endogenous control (RSV-
Renilla), mutated E2F1 (E2F1mut) was determined as luciferase basal activity. ASK1-promoter activity was measured after treatment with TNFa (10 ng/ml) for 24 h using Dual
Luciferase Assay. Results are mean  SD of n ¼ 5 independent experiments. ***p < 0.001 con ASK1WT vs. E2F1mut . ###p < 0.001 TNFa ASK1WT vs. con ASK1WT. $$p < 0.01 con
ASK1mutants vs. con ASK1WT. /^^p < 0.001/0.01 respectively, TNFa ASK1mutants vs. TNFa ASK1WT. (D) HEK-293 cells were transfected with an empty pcDNA3 (EV) or pcDNA3-E2F1
(E2F1WT) and treated with TNFa for 24 h. Next, chromatin was cross-linked, fragmented and subjected to ChIP with a-RNA poll (as positive control e PC), a-ICAM (as negative
control - NC), and a-E2F1 as the protein of interest, as indicated in the Methods. End-point PCR was done using puriﬁed DNA and speciﬁc primers for E2F1 binding site on the
ASK1 promoter; inputs were diluted 1/300 and used as normalization control. Results are mean  SD of n ¼ 3 independent experiments. **/***p < 0.005/0.01 respectively, vs. NC.
$$p < 0.005 vs. EV. HEK-293 cells were transfected with an empty pcDNA3 (EV) or pcDNA3-E2F1 (E2F1WT) and treated with TNFa (10 ng/ml) and SP 600125 (50 mM). Shown are
representative blots of Western blot analysis (E) of cell lysates prepared from HEK-293 cells. b-actin was used as a loading control. (F) HEK-293 cells were transfected with pA3-
ASK1WT or ASK1m3 and pcDNA3-E2F1-mut (E2F1mut) or pcDNA3-E2F1 (E2F1WT). After normalization to endogenous control (RSV-Renilla), pcDNA3-E2F1-mut (E2F1mut) was
determined as luciferase basal activity. ASK1-promoter activity was measured after treatment with TNFa (10 ng/ml) and SP 600125 (50 mM) for 24 h using Dual Luciferase Assay.
Results are mean  SD of n ¼ 3 independent experiments. ***p < 0.001 con ASK1WT (E2F1WT) vs. E2F1mut. ###p < 0.001 TNFa ASK1WT vs. con ASK1WT. $$p < 0.005
TNFa þ SP ASK1WT vs. TNFa ASK1WT. ^p < 0.005 con ASK1m3 (E2F1WT) vs. E2F1mut. ##p < 0.01 TNFa ASK1m3 vs. con ASK1m3. &p < 0.05 TNFa ASK1m3 vs. TNFa ASK1WT.
@p < 0.05 TNFa þ SP ASK1m3 vs. TNFa ASK1m3.
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Figure 5: Effect of ASK1 depletion on phosphorylation of several members of MAP kinase pathway and on leptin/adiponectin expression and secretion in adipocytes.
(A) ASK1 expression in MEF-derived ﬁbroblasts (before differentiation into adipocytes) or MEF-derived adipocyte-like cells (after differentiation into adipocytes) from either WT or
ASK1-ATKO mice was performed using Western blot analysis. Shown are representative blots from one of 5 independent experiments. Vertical white line indicates splicing of the
same membrane for clarity of presentation. (B) Representative images of MEF-derived ﬁbroblasts or MEF-derived adipocyte-like cells were obtained at 10X and 40X by light
microscopy. MEF-derived adipocyte-like cells from WT and ASK1-ATKO were treated with TNFa 10 ng/ml þ IL-1b 10 ng/ml for 24 h and subjected to Western blot analysis. Shown
are representative blots (C) and densitometry graphs (DeH) of n ¼ 6 independent experiments. b-actin was used as a loading control. **/*p < 0.01/0.05 WT TNFa 10 ng/ml þ IL-
1b 10 ng/ml vs. WT con. /^^p < 0.005/0.05 ASK1-ATKO con vs. WT con. ##/#p < 0.01/0.05 ASK1-ATKO TNFa 10 ng/ml þ IL-1b 10 ng/ml vs. WT TNFa 10 ng/ml þ IL-1b 10 ng/ml
$$/$p < 0.01/0.05 ASK1-ATKO TNFa 10 ng/ml þ IL-1b 10 ng/ml vs. ASK1-ATKO con. To measure expression and secretion levels of leptin (I, J) or adiponectin (KeM), medium
(secretion and expression), and lysates (expression) were analyzed by ELISA (leptin and adiponectin) or by Western blot analysis (adiponectin). The results were normalized to cell
protein concentrations. Results are mean  SD of n ¼ 6 independent experiments. *p < 0.05 WT TNFa 10 ng/ml þ IL-1b 10 ng/ml vs. WT con. /^^p < 0.01/0.05 ASK1-ATKO con
vs. WT con.
Original Article
732 MOLECULAR METABOLISM 6 (2017) 725e736  2017 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
resulted in different activation kinetics. Interestingly, tunicamycin, an
inducer of ER stress, did not elicit a similar effect. Supporting the
notion that the increased steady-state mRNA levels could be attributed
to increased transcription (rather than to enhanced mRNA stability), we
observed that actinomycin D, a global transcription inhibitor, fully
prevented the increase in Ask1 mRNA induced by TNFa (Figure 3B).
Next, we set to dissect a putative role for E2f1 in adipocytes by siRNA-
mediated knockdown and by utilizing MEFs from E2F1-KO (E2F1/)
mice that were differentiated into adipocyte-like cells. siRNA targeting
E2f1 decreased the mRNA and protein levels of this gene product in
mature epididymal adipocytes by w90% and 75%, respectively,
compared to a non-targeting (NS) siRNA (Figure 3C). Under these
conditions, TNFa-induced increase in Ask1 mRNA was signiﬁcantly
inhibited by w50% (Figure 3D). We previously demonstrated that
despite the role of E2F1 in adipogenesis [35], under in-vitro conditions,
MEFs from E2F1/ mice can differentiate into adipocyte-like cells
comparably to MEFs from wild-type (WT) mice, as assessed
morphologically and by the similar induction of adipocyte-speciﬁc
genes (Pparg, Cebp4a, Fabp4, and Glut4) [30]. Utilizing these cells,
we observed that in the absence of E2F1, “basal” ASK1 expression
was markedly attenuated (Figure 3EeG). In addition, ASK1 expression
was stimulated by 2.72  0.20-fold by TNFa þ IL-1b in the WT cells,
but only by 1.93  0.08-fold in the E2F1/ adipocyte-like cells
(p ¼ 0.029). Consistently, both basal and TNFa þ IL-1b-stimulated
phosphorylation of JNK (a MAP kinase downstream of ASK1) was
markedly attenuated (Figure 3E,HeI). Thus, in adipocyte cellular
models, decreased E2F1 results in lower ASK1 expression and
attenuated downstream signaling.
To elucidate how elevated E2F1 might increase ASK1 transcription, a
luciferase reporter assay utilizing the human ASK1 promoter region
(1000 toþ500 bp) in HEK293 cells was performed. When cells were
co-transfected with an empty vector plasmid (EV), promoter activity
was low, and it was unresponsive to TNFa stimulation. Upon E2F1
over-expression, two phenomena were observed; basal ASK1 pro-
moter activity was greatly enhanced (by w40-fold, Figure 4A),
consistent with previous reports [28,29], and E2F1 over-expression
permissively sensitized cells to respond to TNFa stimulus by “super-
activating” ASK1 promoter activity >2-fold (Figure 4A). Both the basal
and TNFa-stimulated promoter activity required E2F1 binding to DNA,
since expression of a mutant E2F1 that lacks DNA binding capacity
failed to stimulate luciferase activity (Figure 4A). To further verify the
role of direct binding of E2F1 to the ASK1 promoter, 3 mutants in the
human ASK1 promoter were generated targeting a single putative
E2F1 binding site (see Methods for prediction approach) (Figure 4B).
Both site mutants and a 4 bp deletion mutant signiﬁcantly diminished
ASK1 promoter activity (Figure 4C). Yet, residual E2F1-related activity
was still evident, and in particular, the 2-fold “super-induction” of
ASK1-promoter emediated luciferase activity by TNFa above basal
activity was still evident. Intriguingly, ChIP analysis revealed that E2F1
over-expression indeed increased E2F1 binding to the ASK1 promoter
(Figure 4D). Yet, TNFa-induced “super-activation” of ASK1 promoter
activity under conditions of E2F1 over-expression (Figure 4A) was not
associated with further binding of E2F1 to the ASK1 promoter
(Figure 4D). This suggests that although being permissive for ASK1
promoter “super-activation,” this effect of E2F1-overexpression is
likely indirect, possibly being mediated by TNFa-induced JNK phos-
phorylation/activation. To address this possibility, we assessed
whether a pharmacological JNK inhibitor, SP600125, could alleviate
the TNFa-mediated activation of ASK1 promoter activity under E2F1
overexpression. Indeed, TNFa induced JNK phosphorylation, and the
phosphorylation of its substrate, c-JUN (Figure 4E). SP600125
inhibited JNK activity, since it did not affect TNFa-induced p-JNK while
preventing the phosphorylation of its substrate c-Jun. Under these
conditions, TNFa-induced super-activation of the ASK1 promoter un-
der conditions of E2F1 overexpression was nearly fully inhibited
(Figure 4F). Collectively, we conﬁrm that E2F1 over-expression acti-
vates ASK1 promoter activity and identify a putative binding site for
E2F1 in the human ASK1 promoter. Importantly, we demonstrate that
E2F1 plays a permissive, JNK-mediated, sensitization of the ASK1
promoter to TNF-induced “super-activation.”
3.3. Functional signiﬁcance of adipocyte ASK1
Finally, to unravel the functional role of ASK1 in adipocytes, we utilized
MEFs of wild-type (WT, Cre-, ASK1ﬂ/ﬂ) and ASK1-AT-speciﬁc KO mice
(Creþ, ASK1ﬂ/ﬂ, ASK1-ATKO), which were differentiated into mature
adipocyte-like cells. In non-differentiated MEF (before inducing adi-
pogenesis), ASK1 expression was similar between the two genotypes
(Figure 5A). After inducing adipogenesis, cells morphologically became
adipocyte-like (Figure 5B), and ASK1 expression in the ASK1-ATKO
adipocyte-like cells was lower than in the WT under basal conditions
(Figure 5C,D). Moreover, induction of ASK1 expression by TNFa þ IL-
1b-was lower in the ASK1-ATKO adipocyte-like cells (Figure 5C,D).
Next, we evaluated the effect of ASK1 absence on several members of
the MAP kinase pathway downstream of ASK1. While only mild dif-
ferences were observed in the expression levels of total JNK and total
p-38 between the two types of cells, a signiﬁcant reduction in basal
and TNFaþ IL-1b-stimulated phosphorylation of p-MKK4, p-JNK, and
p-p38 was evident in the cells with lower ASK1 expression
(Figure 5C,D). We next assessed the functional impact of reduced
ASK1 expression. No signiﬁcant differences between the WT and
ASK1-ATKO e derived adipocyte like cells were detected in the
phosphorylation of both basal and insulin-stimulated Akt (Ser-473,
Thr- 308), or total levels of IRS-1 (Supplemental Fig. 1). In contrast, a
signiﬁcant difference in expression and secretion of the key adipokines
leptin and adiponectin was observed using both ELISA and Western
blot analysis. Whereas ASK1-ATKO adipocyte-like cells secreted lower
basal levels of leptin than the WT cells (Figure 5E), the basal adipo-
nectin secretion was signiﬁcantly higher (Figure 5E). As expected,
inﬂammatory conditions (TNFa þ IL-1b) signiﬁcantly lowered leptin
and adiponectin secretion from WT adipocyte-like cells, but less so in
the ASK1-ATKO adipocyte-like cells, indicating that ASK1 mediates the
negative impact of inﬂammation on adipokine secretion (Figure 5EeG).
4. DISCUSSION
This study explores the hypothesis that ASK1, via transcriptional
upregulation by E2F1, molecularly deﬁnes AT that supports a dys-
metabolic obese phenotype in humans. We demonstrate associa-
tions between increased visceral-AT ASK1 expression and multiple
parameters of metabolically-unhealthy obesity, even beyond BMI and
patients’ sub-phenotyping by fat distribution pattern. Associations of
ASK1 with markers of dys-glycemia, dyslipidemia, and systemic
inﬂammation were attenuated by adjusting for E2F1 expression,
suggesting that E2F1 and ASK1 share a common mechanistic
pathway. At the molecular level, in human-AT, E2F1’s occupancy of
the ASK1 promoter increases with BMI, more so in visceral than in
subcutaneous fat, and two adipocyte cellular models of E2F1 knock-
down/knockout demonstrate decreased ASK1 expression and atten-
uated downstream signaling. Furthermore, an E2F1 binding sequence
in the human ASK1 promoter was identiﬁed, and elevated E2F1 was
shown to contribute to increased ASK1 expression by both a direct
transcriptional mechanism and by a JNK-mediated feed-forward loop.
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These render E2F1 over-expressing cells hyper-sensitive to ASK1
upregulation by inﬂammatory stimuli. Finally, the functional impact of
ASK1 is demonstrated by adipocyte-speciﬁc ASK1-KO cells, which
exhibit an improved adipokine secretory proﬁle (secreting less leptin
and more adiponectin, both basally and in response to an inﬂammatory
stimulus).
Obese sub-phenotypes, particularly based on body-fat distribution
patterns (‘apples’ vs ‘pears’), were noticed decades ago [43]. Yet, with
its growing prevalence, obesity requires a better characterization of
obesity sub-phenotypes for a more stratiﬁed/personalized manage-
ment of the disease. Differences in ATs’ adaptation to chronic caloric
surplus can serve as an effective means of patient stratiﬁcation. For
example, adipocyte size, indicating the reliance of AT expansion on
hypertrophy, has been shown as a potentially clinically-useful tool to
stratify obesity-related type 2 diabetes risk [44e46]. Other histo-
pathological features of a dysfunctional AT include altered cellular
composition of the tissue, in particular macrophage inﬁltration and lipid
accumulation (foam cells) [36,38,47,48], and AT ﬁbrosis [49,50]. Yet, a
molecular deﬁnition of AT signatures that deﬁnes metabolically-
unhealthy obese sub-phenotype(s) has not been systematically
attempted. In oncology, molecular typing of tumors largely relies on the
identiﬁcation of different tumors’ genetic perturbations, increasingly
used to guide patients’ management [51]. Genetic polymorphisms
related to obesity sub-phenotypes and/or responses to therapy are just
beginning to be unraveled [52]. Nevertheless, molecular pathways that
mediate AT stresses could constitute promising leads for molecular-
based obesity sub-phenotyping and personalized treatment.
Along this line, MAP kinases, and in particular the stress-activated
MAP kinases [53], are promising candidates. Indeed, different mem-
bers of this family of kinases, including p38MAP kinase, JNK, and
upstream kinases such as the MAP3K’s Tpl-2 and ASK1, and even
MAP4K’s, have been shown to regulate AT/adipocyte biology and to be
activated in obesity [14e18,54]. MAP kinases are frequently shown to
be regulated by rapid phosphorylation-dephosphorylation [55], and,
indeed, phosphorylation-based activation of a MAP kinase pathway
consisting of ASK1eMKK4,3/6eJNK/p38MAP kinase has been
demonstrated in obese humans’ visceral-AT [18,19]. Yet, we previ-
ously proposed that a signiﬁcant level of regulation may be attributed
to the expression level of these MAP kinases, reﬂecting a more chronic
adaptation of AT in obesity [18]. Moreover, the association between
ASK1 mRNA levels in visceral-AT and insulin resistance, which
remained signiﬁcant even after adjusting for BMI, supported the notion
that ASK1 expression levels may deﬁne obese sub-phenotypes, i.e.
that higher levels of visceral ASK1 may molecularly deﬁne obese
persons with a more dys-metabolic “type” of obesity [18].
Findings of the present study provide a molecular mechanism for the
elevated ASK1 expression in obesity and how it may be functionally
linked to whole-body insulin resistance. The role our ﬁndings assign to
increased E2F1 in upregulating ASK1 parallels the capacity of this
transcription factor to regulate the expression of autophagy genes [56],
reminiscent of previous observations in cancer cells [27e29]. The
transcriptional activity of E2F1 is regulated at multiple levels, including
expression, cellular (nuclear) localization, post-translational modiﬁca-
tions, and multiple interacting proteins. Here, increased E2F1
expression parallels with increased E2F1 binding to the ASK1 promoter
in human adipose tissue explants. Regardless of potential inter-
relations between the ASK1-MAP kinase pathway and autophagy
activation, which have yet to be explored, both pathways downstream
of E2F1 jointly form a signaling network that molecularly deﬁnes
dysfunctional AT. The functional outcome of ASK1 activation in AT is
linked to decreased adiponectin secretion. Intriguingly, up-regulated
autophagy in obese adipose tissue was also shown to result in a
dys-metabolic secretory function of adipocytes characterized by low
adiponectin release, which induced insulin resistance in liver cells [57].
Our study assigns novel insights on the impact of dysregulated ASK1
expression beyond current literature. In either human muscle [23] or at
the whole-body expression level in mice [24], it was decreased
expression of ASK1 that was tied to insulin resistance and/or reduced
energy expenditure, respectively. Here, we demonstrate upregulated
ASK1 expression in visceral AT as a putative link between obesity-
related AT stress and metabolic dysfunction.
In summary, we propose a stress signaling network composed of
E2F1eASK1-MAP kinase and E2F1-autophagy, which molecularly
deﬁnes a metabolically-detrimental obese sub-phenotype in human
adipose tissue. Functionally, by negatively affecting AT endocrine
function, it may link obesity via adipose tissue stress to whole-body
metabolic dysfunction.
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